 | 
| |
Nile is currently advancing two drug candidates for the potential treatment of cardiovascular and renal disease.
CD-NP
- The company's lead product candidate is currently being evaluated in a Phase 2 trial in ~75 ADHF patients.
- Interim top-line results suggest that CD-NP is well-tolerated at dose levels of 1.25 and 2.5 ng/kg/min. Full results expected in late 2010.
- CD-NP may ultimately be useful in several cardiovascular and renal indications beyond ADHF, including:
- Treatment in patients immediately following a heart attack
- Protection of the kidneys in patients undergoing cardiac bypass surgery
- Protection of the kidneys in patients receiving imaging contrast
CU-NP
- Pre-clinical program evaluating the opportunity for chronic dosing of CU-NP for the potential treatment of a number of cardiovascular and renal diseases.
| |
|
